The global infection control market size was estimated at USD 150.4 billion in 2016 and is anticipated to grow at a CAGR of 6.2% throughout the forecast period. The market is predominantly driven by growing number of surgical procedures that require high-intensity infection prevention. The high preference is presumed to be a consequence of positive clinical outcomes associated with usage of infection control.
U.S. infection control market by type, 2014 - 2025 (USD Billion)
The rising number of government initiatives to ensure high degree infection prevention is presumed to be a significant driver of the market. The government organizations are increasingly involved in issuing guidelines in order to promote awareness pertaining to efficient prevention measures globally, which is expected to contribute to the market growth throughout the forecast period.
For instance, the World Health Organization (WHO) has issued guidelines for the prevention and control of pandemic- and epidemic-prone acute respiratory diseases in healthcare. The guidelines range from standard precautions such as hand hygiene, usage of personal protective equipment, to guidelines for disinfection, and sterilization.
According to the statistics published by WHO, Acute Respiratory Diseases (ARDs) is one of the major causes of high mortality rates globally. Approximately 4.0 million deaths occur every year due to ARDs. The aforementioned statistics exemplify the high need for stringent prevention and control.
Diseases such as pneumonia and infections such as bloodstream, urinary tract, surgical site, MRSA constitute majority of the overall hospital-acquired infections. Other major hospital-acquired infections (HAI) include catheter-associated urinary tract infections, ventilator-associated pneumonia, and catheter-related bloodstreams. HAI is believed to be one of the major concerns, that affects patient recovery, thereby, creating a major impact on mortality rates globally.
According to a practical guide published by the WHO on the prevention of HAI, the increase in hospitalization duration with surgical infections was found to be approximately 8 days. These prolonged stays are predicted to be a significant contributor to the overall costs, incurred during the hospitalization period, thus, raising the clinical urgency for adoption of infection prevention measures.
It is presumed that prolonged hospital stay is also not economical for the hospitals and healthcare payers as a consequence of excessive usage of resources to treat the acquired infection. These additional costs are majorly generated through increased usage of drugs, additional diagnostic studies, laboratory equipment, creating a resource allocation imbalance.
In 2016, consumables constituted the largest share of the type segment. The dominant share captured by consumables is predicted to be a consequence of consistent usage and the short life cycle possessed by these products. Consumables are being extensively incorporated in disinfection, sterilization & other control procedures and are indispensable part of the aforementioned procedures, thereby, accounting for a larger share.
Under consumables, personal protective equipment held a substantial share in 2016. Various healthcare organizations are advocating and promoting awareness pertaining to the benefits of personal protective equipment, which is anticipated to be responsible for the significant share. For instance, the WHO, released guidelines in 2014 covering recommendations and strategies for usage of all major infection control products, including personal protective equipment.
These organizations also strive to promote the adoption through issuing guidelines and recommendations for selection, risk assessment, rational usage, removal, considerations to reduce the risk of transmission of respiratory pathogens to healthcare workers and other medical staff within a healthcare facility.
In the type segment, services are expected to grow at a lucrative rate throughout the forecast period. This fastest growth is attributed to the high inclination of market players to reduce overall healthcare expenditure along with utilization of benefits involved. It primarily includes cost advantages, increased efficiency of services, enhanced productivity, and a significantly higher focus on the core areas of development, which are highly critical to a company’s overall profit and growth.
Hospitals held a dominant share with a share in the end-use segment in 2016 and are anticipated to attain growth at the fastest CAGR throughout the forecast period. The substantial share is majorly a consequence of high probability of acquiring infections in hospital premises through respiratory or bloodborne pathogen transmission.
HAIs are one of the major challenges and thus require stringent control. This has urged hospitals and public health organizations to adopt highly efficient control systems. Also, as per research published in NCBI, 40% to 60% of hospital infections were estimated to be of surgical sites.
Global infection control market share, by end-use, 2016 (%)
High risk of infection from bloodborne pathogens, drug-resistant pathogens, and others in the operating room is one of the major concerns. For instance, frequent usage of urinary catheters poses a high risk of UTIs and may result in catheter-associated (CA)-UTIs. According to research published in NCBI, UTIs account for 25% of all bacterial infections.
As per the data published in the National Nosocomial Infection Surveillance (NNIS) system report, most hospital-acquired UTIs are associated with catheterization and CA-bacteriuria is the most frequently occurring HAI globally, accounting for up to 40% of HAIs in the U.S. each year. These factors are expected to widen the future growth prospects of the market.
In 2016, North America accounted for a dominant share of the market. A consistent number of strategic collaborations adopted by key market players to widen their product portfolio and infection control capabilities are believed to be responsible for the greater share captured by this region.
In addition, increasing efforts by the established companies to widen their presence across this region is responsible for the dominant share of captured by North America. For instance, In January 2017, Advanced Sterilization Products launched the STERRAD 100NX System with ALLClear in the U.S and is planning to expand its footprint into regions such as Europe, Africa, and Middle East.
The Asia Pacific market is expected to exhibit the fastest CAGR throughout the forecast period owing to the growing presence of outsourcing organizations, growing healthcare expenditure, and unprecedented evolution of the healthcare standards & infrastructure across this region. The presence of various voluntary and government organizations focused on improving infection control standards is also one of the significant factors contributing to the growth of the Asia Pacific region.
Increasing trend of outsourcing by established market players in developed economies, to companies in Asia Pacific region, also serve as key growth impelling factors for the market. For instance, the Asia Pacific Society of Infection Control (APSIC) is a voluntary organization working in the direction of establishing collaborative partnerships to facilitate quality improvement and conduct infection control research to promote cost-efficient practices throughout the Asia Pacific region.
The competition is marked by extensive implementation of collaborative strategies by major companies such as Advanced Sterilization Products, STERUS Corporation, Cantel Medical Corporation, which accounts for their dominant market share. These players are highly focused on adopting competitive strategies such as mergers & acquisitions, new product development initiatives, and geographical expansion.
For instance, in March 2017, 3M and Kimberly-Clark Health Care signed an alliance to co-develop and deliver surgical and infection prevention solutions utilizing their respective expertise. The details of the deal were not disclosed but are expected to be implemented by the end of 2017.
Similarly, in July 2016, 3M launched a four-hour rapid readout biological indicator for vaporized hydrogen peroxide sterilization, designed to give results in 4 hours and monitored steam sterilization loads. The product was launched to expand the company’s product portfolio.
Report Attribute |
Details |
Market size value in 2020 |
USD 189.65 billion |
Revenue forecast in 2025 |
USD 258.3 billion |
Growth Rate |
CAGR of 6.2% from 2017 to 2025 |
Base year for estimation |
2016 |
Historical data |
2014 - 2016 |
Forecast period |
2017 - 2025 |
Quantitative units |
Revenue in USD million and CAGR from 2017 to 2025 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Type, end use, region |
Regional scope |
North America; Europe; APAC; Latin America; MEA |
Country scope |
U.S.; Canada; UK; Germany; Japan; China; Brazil; Mexico; South Africa |
Key companies profiled |
3M Company; Belimed AG; Halyard Health, Inc.; Getinge Group; Advanced Sterilization Products; Matchana Group; Sterigenics International; MMM Group; Cantel Medical Corporation; STERUS Corporation |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional & country levels and provides an analysis of the industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global infection control market; on the basis of type, end use, and region:
Type Outlook (Revenue, USD Billion, 2014 - 2025)
Equipment
Disinfectors
Washers
Flushers
Endoscope Reprocessors
Sterilization equipment
Heat Sterilization Equipment
Low Temperature Sterilization Equipment
Radiation Sterilization Equipment
Filtration Sterilization Equipment
Liquid Sterilization Equipment
Others
Services
Contract Sterilization
Ethylene Oxide Sterilization
E-beam Sterilization
Gamma Sterilization
Others
Infectious Waste Disposal
Consumables
Infectious Waste Disposal
Disinfectants
Sterilization Consumables
Personal Protective Equipment
Others
End-use Outlook (Revenue, USD Billion, 2014 - 2025)
Hospitals
Medical Device Companies
Clinical Laboratories
Pharmaceutical Companies
Others
Regional Outlook (Revenue, USD Billion, 2014 - 2025)
North America
The U.S.
Canada
Europe
UK
Germany
Asia Pacific
Japan
China
India
Latin America
Mexico
Brazil
Middle East & Africa
South Africa
b. The global infection control market size was estimated at USD 178.75 billion in 2019 and is expected to reach USD 189.65 billion in 2020.
b. The global infection control market is expected to grow at a compound annual growth rate of 6.2% from 2018 to 2025 to reach USD 258.28 billion by 2025.
b. North America dominated the infection control market with a share of 34.48% in 2019. This is attributable to growing number of surgical procedures that require high intensity infection prevention.
b. Some key players operating in the infection control market include 3M Company, Belimed AG, Halyard Health, Inc., Getinge Group, Advanced Sterilization Products, Matchana Group, Sterigenics International, MMM Group, Cantel Medical Corporation, and STERUS Corporation.
b. Key factors that are driving the market growth include rising number of government initiatives to ensure high degree infection prevention.
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.